NCT06525974View on ClinicalTrials.gov

Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With Mesalamine

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

46

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

December 30, 2026

Conditions

Ulcerative Colitis

Interventions

DRUG

Febuxostat

40mg of Febuxostat once daily

DRUG

Mesalamine

1 g mesalamine three times daily for 3 months.

All Listed Sponsors

lead

Tanta University

OTHER